Compare AbCellera Biologics Inc (ABCL) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Baker Hughes Co — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Baker Hughes Co trades at $56.94 (market cap $54.04B). The key difference: Baker Hughes Co is far larger — about 23× AbCellera Biologics Inc's market cap, and Baker Hughes Co pays a 1.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BKR | |
|---|---|---|
Market Cap | $2.35B | $54.04B |
Sector | Health | Energy |
52-Week High | $8.12 | $69.67 |
52-Week Low | $2.78 | $38.68 |
Enterprise Value | $1.99B | $55.44B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Baker Hughes (BKR) trades at $54.47, up 3.2% over the past 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Recent contract wins in Angola and Nigeria, along with expansion into geothermal energy, highlight growth initiatives. Financials show strong profitability with an 11.17% net income margin and improving cash flow trends, though revenue growth has moderated.
The outlook for BKR is positive, supported by analyst consensus with a $74.27 price target and 66.7% buy ratings. Key opportunities include energy transition projects and international contracts, while risks involve oil price volatility and integration challenges from the Chart Industries acquisition. The stock presents a value opportunity with a P/E of 17.01, trading below analyst targets amid operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
